ALT Altimmune, Inc. Stock Quote

ALT [NASD]

Index	-	P/E	-	EPS (ttm)	-2.41	Insider Own	0.80%	Shs Outstand	43.97M	Perf Week	-4.55%
Market Cap	191.68M	Forward P/E	-	EPS next Y	-2.30	Insider Trans	-7.98%	Shs Float	40.86M	Perf Month	4.05%
Income	-101.70M	PEG	-	EPS next Q	-0.47	Inst Own	78.60%	Short Float	9.43%	Perf Quarter	-39.61%
Sales	3.60M	P/S	53.25	EPS this Y	-22.90%	Inst Trans	3.85%	Short Ratio	4.55	Perf Half Y	-55.83%
Book/sh	4.20	P/B	1.10	EPS next Y	-9.80%	ROA	-44.30%	Target Price	23.14	Perf Year	-63.51%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-48.70%	52W Range	3.83 - 19.46	Perf YTD	-49.56%
Dividend	-	P/FCF	-	EPS past 5Y	45.70%	ROI	-48.70%	52W High	-76.26%	Beta	1.36
Dividend %	-	Quick Ratio	10.00	Sales past 5Y	6.40%	Gross Margin	-	52W Low	20.63%	ATR	0.39
Employees	47	Current Ratio	10.00	Sales Q/Q	41.70%	Oper. Margin	-	RSI (14)	45.44	Volatility	7.23% 8.45%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-15.70%	Profit Margin	-	Rel Volume	0.41	Prev Close	4.72
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 BMO	Payout	-	Avg Volume	847.84K	Price	4.62
Recom	1.70	SMA20	-0.25%	SMA50	-14.19%	SMA200	-50.02%	Volume	346,013	Change	-2.12%

Dec-29-21

Resumed

Jefferies

Buy

$30

Jun-02-21

Initiated

H.C. Wainwright

Buy

$35

Feb-11-21

Initiated

Guggenheim

Buy

$36

Dec-14-20

Initiated

Jefferies

Buy

$25

Nov-12-20

Reiterated

B. Riley Securities

Buy

$31 → $28

Sep-25-20

Initiated

B. Riley FBR

Buy

$31

Aug-14-20

Initiated

Evercore ISI

Outperform

Jul-31-20

Initiated

Piper Sandler

Overweight

$80

Jul-28-20

Initiated

JMP Securities

Mkt Outperform

$50

Feb-24-20

Resumed

ROTH Capital

Buy

$13

Jul-19-19

Initiated

ROTH Capital

Buy

$8.30

Oct-09-17

Initiated

Piper Jaffray

Overweight

May-23-22 09:55AM	Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High? Zacks
May-20-22 07:30AM	Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022 GlobeNewswire
May-16-22 07:30AM	Altimmune to Present at Upcoming Investor Conferences GlobeNewswire -6.78%
May-14-22 09:51AM	Altimmune (NASDAQ:ALT) surges 19% this week, taking three-year gains to 111% Simply Wall St.
May-12-22 07:00AM	Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire +8.63%
May-05-22 07:30AM	Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12 GlobeNewswire -6.21%
Apr-01-22 03:40PM	What Kind Of Investors Own Most Of Altimmune, Inc. (NASDAQ:ALT)? Simply Wall St.
07:00AM	Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity GlobeNewswire
Mar-22-22 12:47PM	The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider TipRanks
Mar-15-22 07:01AM	Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update GlobeNewswire -8.24%
Mar-08-22 07:00AM	Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022 GlobeNewswire
Feb-17-22 03:02PM	Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for Zacks -5.30%
Jan-31-22 07:00AM	Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity GlobeNewswire +12.08%
Jan-28-22 04:36AM	Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation Simply Wall St. +10.26%
Jan-24-22 02:48PM	It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. American City Business Journals
Jan-03-22 07:00AM	Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022 GlobeNewswire
Dec-13-21 06:00AM	Altimmune Appoints Richard Eisenstadt as Chief Financial Officer GlobeNewswire
06:00AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-22-21 04:01PM	Altimmune to Present at Upcoming Investor and Scientific Conferences GlobeNewswire
Nov-10-21 04:01PM	Altimmune to Present at Upcoming Investor Conferences GlobeNewswire
Nov-09-21 04:01PM	Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update GlobeNewswire
Nov-03-21 04:01PM	Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021 GlobeNewswire
Nov-01-21 03:01PM	Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-15-21 09:35PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT PR Newswire
Oct-13-21 04:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT ACCESSWIRE
Oct-11-21 03:51PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT GlobeNewswire
Oct-06-21 04:01PM	Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021 GlobeNewswire
Oct-04-21 07:00AM	Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease GlobeNewswire -5.27%
Oct-03-21 08:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT GlobeNewswire
Oct-01-21 05:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT Newsfile +5.66%
01:00PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Altimmune, Inc. (ALT) Investigation ACCESSWIRE
Sep-29-21 06:15PM	Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021 GlobeNewswire -13.84%
Sep-28-21 07:01AM	Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers GlobeNewswire
05:00AM	Greater Washington's scientists recount the highs and lows of researching and testing Covid-19 vaccines American City Business Journals
Sep-27-21 04:01PM	Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021 GlobeNewswire
Sep-17-21 06:12AM	Shareholders Will Likely Find Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Acceptable Simply Wall St. -7.07%
Sep-07-21 04:01PM	Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 GlobeNewswire
Sep-02-21 06:21AM	Do Institutions Own Altimmune, Inc. (NASDAQ:ALT) Shares? Simply Wall St.
Aug-27-21 08:31AM	Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock? Zacks
Aug-10-21 04:01PM	Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update GlobeNewswire
Aug-04-21 04:01PM	Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021 GlobeNewswire
Aug-03-21 03:00PM	Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know Zacks +5.52%
Jul-04-21 03:39AM	Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jun-29-21 04:01PM	Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial GlobeNewswire
Jun-17-21 01:15AM	Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock? Zacks
Jun-16-21 07:00AM	Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers GlobeNewswire +16.49%
May-27-21 07:00AM	Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference GlobeNewswire
May-26-21 07:00AM	Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID GlobeNewswire +7.29%
May-25-21 09:21AM	Do Options Traders Know Something About Altimmune (ALT) Stock We Don't? Zacks
May-17-21 07:00AM	Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update GlobeNewswire +5.98%
06:45AM	Altimmune, Inc. to Host Earnings Call ACCESSWIRE
May-11-21 07:00AM	Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021 GlobeNewswire
May-10-21 07:00AM	Altimmune Announces New Preclinical Data for AdCOVID Demonstrating Sterilizing Immunity After a Single Intranasal Dose GlobeNewswire
May-05-21 03:00PM	Earnings Preview: Altimmune, Inc. (ALT) Q1 Earnings Expected to Decline Zacks
01:50AM	The Altimmune (NASDAQ:ALT) Share Price Has Soared 339%, Delighting Many Shareholders Simply Wall St.
Apr-29-21 07:00AM	Altimmune to Present at Upcoming Scientific Conferences GlobeNewswire
Apr-03-21 03:07AM	A Look At The Fair Value Of Altimmune, Inc. (NASDAQ:ALT) Simply Wall St.
Apr-01-21 07:00AM	Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield GlobeNewswire
Mar-25-21 11:46AM	ORMP: Company Advancing Oral COVID-19 Vaccine Zacks Small Cap Research +6.97%
Mar-22-21 07:00AM	Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID Vaccine Candidate GlobeNewswire
Mar-15-21 07:00AM	AdCOVID, Altimmunes Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection GlobeNewswire +5.79%
Mar-14-21 05:55AM	Altimmune Extends Lonza Partnership To Support Production Of AdCOVID SmarterAnalyst
Mar-12-21 01:00AM	Altimmune Expands AdCOVID Manufacturing Collaboration with Lonza GlobeNewswire
Mar-09-21 09:40AM	Altimmune Joins Rank Of Stocks With RS Ratings Over 90 Investor's Business Daily +13.22%
Mar-08-21 04:01PM	Altimmune to Present at Upcoming Conferences GlobeNewswire
Feb-25-21 11:15PM	Altimmune, Inc. (NASDAQ:ALT): Is Breakeven Near? Simply Wall St. -12.16%
11:26AM	Positive news on COVID vaccines weighs against concerns over new variants MarketWatch
10:42AM	Altimmune starts enrolling early-stage trial for its nasal spray COVID-19 vaccine candidate MarketWatch
07:03AM	Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate GlobeNewswire
07:00AM	Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update GlobeNewswire
06:30AM	Altimmune, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 04:30PM	Altimmune To Announce Year End 2020 Financial Results on February 25, 2021 GlobeNewswire -14.70%
Feb-18-21 10:24AM	Altimmune to start early-stage trial for its COVID-19 vaccine candidate MarketWatch
Feb-17-21 07:02AM	Altimmune Announces FDA Clearance of AdCOVID IND Application GlobeNewswire +13.86%
Feb-01-21 10:30AM	BPTN donates $10,000 to two Black-owned nonprofits serving youth in Toronto and Atlanta CNW Group +17.02%
Jan-14-21 11:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT ACCESSWIRE
Jan-11-21 11:23PM	Is Altimmune, Inc. (NASDAQ:ALT) Popular Amongst Institutions? Simply Wall St. -5.31%
10:40PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT Newsfile
Jan-06-21 11:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT ACCESSWIRE
Jan-04-21 09:46PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT PR Newswire +12.68%
Dec-30-20 08:00AM	Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B GlobeNewswire
Dec-23-20 04:01PM	Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID Clinical Trial GlobeNewswire -6.86%
Dec-16-20 03:51PM	Where Do Hedge Funds Stand On Altimmune, Inc. (ALT)? Insider Monkey
Dec-11-20 07:00AM	Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference GlobeNewswire
Dec-08-20 08:00AM	Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH GlobeNewswire
Nov-25-20 07:00AM	Altimmune Announces Submission of Investigational New Drug Application for AdCOVID a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December GlobeNewswire +9.08%
Nov-16-20 07:00AM	Altimmune to Present at Upcoming Virtual Investor Conferences GlobeNewswire -7.01%
Nov-13-20 05:23AM	Altimmune, Inc. (NASDAQ:ALT) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Nov-10-20 01:00AM	Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19 GlobeNewswire +19.08%
Nov-09-20 04:05PM	Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire -37.07%
Nov-03-20 08:00AM	Altimmune to Announce Third Quarter 2020 Financial Results on November 10 GlobeNewswire
Oct-30-20 02:40PM	3 Biotech Stocks in the Hunt for COVID-19 Vaccine; One Analyst Calls Them a Buy TipRanks
Oct-26-20 06:22AM	Imagine Holding Altimmune (NASDAQ:ALT) Shares While The Price Zoomed 494% Higher Simply Wall St.
Oct-15-20 07:00AM	Altimmune to Present at Two Upcoming Virtual Investor Conferences GlobeNewswire
Oct-13-20 04:56AM	Altimmunes COVID-19 Vaccine Shows Positive Results; Street Sees 289% Upside SmarterAnalyst +12.86%
Oct-12-20 07:01AM	Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID Intranasal COVID-19 Vaccine Candidate GlobeNewswire
Sep-30-20 07:00AM	Altimmune to Present at Upcoming Investor Conferences GlobeNewswire
Sep-28-20 04:01PM	Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs AdCOVID and T-COVID at the World Vaccine Congress GlobeNewswire
Sep-01-20 07:00AM	Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH GlobeNewswire -10.55%
Aug-27-20 08:17AM	Altimmune, Inc.'s (NASDAQ:ALT) Path To Profitability Simply Wall St.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Drutz David	Director	May 24	Buy	4.50	1,200	5,400	19,012	May 25 07:00 PM
Harris Matthew Scott	Chief Medical Officer	Feb 28	Option Exercise	1.92	30,000	57,639	41,545	Mar 02 07:00 PM
Harris Matthew Scott	Chief Medical Officer	Feb 28	Sale	7.52	30,000	225,600	11,545	Mar 02 07:00 PM
Roberts M Scot	Chief Scientific Officer	Feb 01	Option Exercise	0.00	6,166	0	19,883	Feb 03 07:55 PM
Garg Vipin K	President and CEO	Feb 01	Option Exercise	0.00	16,545	0	300,503	Feb 03 07:56 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01	Option Exercise	0.00	6,166	0	13,728	Feb 03 07:56 PM
Drutz David	Director	Jan 25	Option Exercise	2.40	70	168	17,882	Jan 26 07:00 PM
Drutz David	Director	Dec 14	Option Exercise	2.40	139	334	17,812	Dec 15 07:00 PM
Drutz David	Director	Nov 19	Option Exercise	2.40	70	168	17,673	Nov 19 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience